FDA orders NAION eye warning on all GLP-1 drugs, including Ozempic, Wegovy and Mounjaro
The US Food and Drug Administration said on 9 November 2026 that every GLP-1 receptor agonist, from Ozempic and Wegovy to Mounjaro, Zepbound and the new pill Foundayo, must carry a warning about a potential increased risk of NAION, a rare optic-nerve condition that can cause sudden, sometimes permanent, vision loss in one eye. The FDA called the risk potential and rare; it did not restrict any approved use.
Kabeer Ahmad8 min read